key: cord-0820735-okq0h4ng
authors: Bhalla, Anurag; Mukherjee, Manali; Radford, Katherine; Nazy, Ishac; Kjarsgaard, Melanie; Bowdish, Dawn M.E.; Nair, Parameswaran
title: Dupilumab, Severe Asthma Airway Responses, and SARS‐CoV2 Serology
date: 2020-08-06
journal: Allergy
DOI: 10.1111/all.14534
sha: 136c0799e0d280140b045c6e5e97420909d21eac
doc_id: 820735
cord_uid: okq0h4ng

There is paucity of evidence assessing immune responses to COVID‐19 in severe asthmatics treated with biologics. Recent guidelines recommend continuing these agents (as clinically indicated) to maintaining asthma control. Supporting this claim, Lommatzsch demonstrated that omalizumab could safely be continued during active COVID‐19 infection in a patient with allergic asthma.(1) There are other emerging reports that show that treatment with benralizumab(2) and dupilumab(3) is not associated with significant negative impact. We had similar experience in a young patient with severe asthma treated with dupilumab.

This article is protected by copyright. All rights reserved Dr. Nair is supported by the Frederick E. Hargreave Teva Innovation Chair in Airway Diseases. He has received honoraria from AZ, Sanofi, Teva, Merck, Novartis and Equillium and his university has received research grants from AZ, Teva, Sanofi, Novartis, BI and Methapharm.

To the editors:

There is paucity of evidence assessing immune responses to COVID-19 in severe asthmatics treated with biologics. Recent guidelines recommend continuing these agents (as clinically indicated) to maintaining asthma control. Supporting this claim, Lommatzsch demonstrated that omalizumab could safely be continued during active COVID-19 infection in a patient with allergic asthma. 1 There are other emerging reports that show that treatment with benralizumab 2 and dupilumab 3 is not associated with significant negative impact. We had similar experience in a young patient with severe asthma treated with dupilumab. However, her immunoglobulin responses to the virus were modest compared to two other patients who had not previously been exposed to dupilumab. We speculate if interruption of IL-4 receptor signalling may prolong the development of antibody responses to SARS-CoV2.

A 23-year-old female, who had predominant IL-4/IL-13-driven disease (characterized by atopy, severe airway hyperresponsiveness with PC20 methacholine 0.08mg/ml, mucus hypersecretion, sputum and blood eosinophilia, and FeNO of 74ppb), noticed significant improvement in asthma control (ACQ-5: 1, 26% improvement in FEV1) after receiving dupilumab (600mg loading dose followed by 300mg every 2 weeks, subcutaneously) from September-December of 2019 (NCT03884842; clinicaltrials.gov). In mid-March of 2020, she tested positive by PCR of a nasopharyngeal (NP) swab for SARS-CoV2. Her asthma was uncontrolled (ACQ-5: 4.4) but her blood eosinophils were normal (0.1x10 9 /L). Sputum and spirometry were not examined. She remained on high doses of inhaled corticosteroids (800µg mometasone) and formoterol, and her ACQ-5 gradually improved over the following 8 weeks to

This article is protected by copyright. All rights reserved 3.0. Blood eosinophils went up to 1.4x10 9 /L, but sputum eosinophils were normal at 1%, FeNO was 15ppb and FEV1 was 2.2L (70% predicted). However, 9 weeks after her onset of symptoms, the virus was still detectable by PCR from her NP swab. There was insufficient viral load to attempt viral culture.

We examined some potential mechanisms to investigate if dupilumab may have contributed to the infection (by modulating ACE2 or TMPRSS2 expression) and the prolonged viral detection (by modulating anti-SARS-CoV2 antibody levels). ACE2 could not be detected in her sputum samples but TMPRSS2 expression had increased 4-fold (by RT-PCR normalized to GAPDH housekeeping gene, using validated primers from Bio-Rad, CA, USA). It is plausible that the high dose of inhaled steroids decreased ACE2 expression 4 but probably did not affect TMPRSS2 expression that facilitated the infection. Inhaled steroids also probably prevented significant asthma deterioration and respiratory distress. Indeed, dexamethasone was demonstrated to improve COVID-19 outcomes in hospitalized patients. 5 Additionally, serum antibodies (IgA, IgM and IgG) to two SARS-CoV2 antigens, the Spike-protein (S) and receptorbinding-domain (RBD) were measured using an ELISA to purified recombinant proteins as previously described 6 in our index patient and two other control patients who developed the infection (an asthmatic on inhaled steroid only (fluticasone 500µg daily) and a steroid-naïve nonasthmatic). In comparison to two control patients, the dupilumab-treated patient had blunted IgG and IgM and absent IgA antibodies to two SARS-CoV2 antigens, the Spike-protein and receptorbinding-domain (figure). It is unclear if previous treatment with dupilumab may have led to a less robust antibody response or reduced class switching, although this has not been observed with T-cell-dependent and T-cell-independent humoral immune responses to tetanus and meningococcal vaccines. 7 Lastly, our index patient had relative eosinopenia at the time of

This article is protected by copyright. All rights reserved diagnosis, which has been associated with increased symptoms and a longer disease course, whereas high blood eosinophils are associated with COVID-19 recovery. 8 In conclusion, we suggest that while dupilumab, when used along with glucocorticosteroids for asthma may be safe during SARS-CoV2 infection, further research is necessary to understand its effect on the sero-immune responses to the virus, and whether it may prolong the time to recover from the infection. 

COVID-19 in a patient with severe asthma treated with Omalizumab

COVID-19, severe asthma, and biologics. Annals of allergy, asthma & immunology : official publication of the American College of Allergy

COVID-19 in a patient with severe chronic rhinosinusitis with nasal polyps during therapy with dupilumab

COVID-19 Related Genes in Sputum Cells in Asthma: Relationship to Demographic Features and Corticosteroids

Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report. medRxiv

A serological assay to detect SARS-CoV-2 seroconversion in humans

Dupilumab does not affect correlates of vaccineinduced immunity: A randomized, placebo-controlled trial in adults with moderate-tosevere atopic dermatitis

Patients of COVID-19 may benefit from sustained Lopinavircombined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression

This article is protected by copyright. All rights reserved cut-off value (optical density +2 standard deviations for pre-COVID plasma) and optical density values are divided by this cut-off value. Levels above one are considered positive (dashed line).Dupilumab-treated patient remained PCR positive for 9 weeks, while the non-dupilumab-treated patients tested negative between 4 and 5 weeks.